Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference
September 22 2017 - 07:15AM
Business Wire
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and
developing drugs to treat cancer, today announced that the company
will present at the Cantor Fitzgerald Global Healthcare Conference
on Monday, September 25th at 8:35 a.m. ET at the InterContinental
New York Barclay Hotel in New York.
A live audio webcast of the presentation will be available on
the company’s website at www.verastem.com. An archived
presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company
focused on discovering and developing drugs to improve outcomes for
patients with cancer. Verastem is currently developing duvelisib, a
dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully
met the primary endpoints in both a Phase 2 study in
double-refractory iNHL and a Phase 3 clinical trial in patients
with relapsed/refractory CLL/SLL. In addition, Verastem is
developing the FAK inhibitor, defactinib, which is currently being
evaluated in three separate clinical collaborations in combination
with immunotherapeutic agents for the treatment of several
different cancer types, including pancreatic, ovarian, non-small
cell lung cancer, and mesothelioma. Verastem’s product candidates
seek to treat cancer by modulating the local tumor
microenvironment, enhancing anti-tumor immunity and reducing cancer
stem cells. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170922005297/en/
Verastem, Inc.Brian Sullivan, 781-292-4214Director,
Corporate Developmentbsullivan@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2023 to Mar 2024